Margreet G. Franken

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model.

Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 20, 2024

A blueprint for health technology assessment capacity building: lessons learned from Malta.

A blueprint for health technology assessment capacity building: lessons learned from Malta.

Journal: International journal of technology assessment in health care

Published: February 28, 2024

Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab.

Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab.

Journal: PloS one

Published: July 23, 2023

A SWOT analysis of the complex interdependencies of the Maltese reimbursement processes.

A SWOT analysis of the complex interdependencies of the Maltese reimbursement processes.

Journal: Health policy OPEN

Published: September 16, 2022

Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Journal: Annals of surgical oncology

Published: March 07, 2022

Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs.

Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs.

Journal: ESMO open

Published: April 21, 2021

Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands.

Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands.

Journal: Melanoma research

Published: April 19, 2021

Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma.

Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma.

Journal: JAMA network open

Published: March 29, 2021

Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003-2018): A nationwide population-based study.

Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003-2018): A nationwide population-based study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 02, 2021

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.

Journal: BMC cancer

Published: October 19, 2020

Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs.

Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs.

Journal: Cancers

Published: March 19, 2020

Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy.

Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy.

Journal: Cancers

Published: March 06, 2020

Showing 1-12 of 41

Last Updated: 09/26/2026